Investor Relations

The pace is accelerating. Not leveling off.

New blind validations, new patent filings, and new drug targets have landed roughly every two weeks this summer. We are raising now to match the pace of the science.

$157B

Current addressable market in Oncology and Rare Disease - growing to $350B+ with Agriculture and Industrial

36/36

Blind predictions correct - cryptographically locked before literature was checked. 100% record.

USPTO provisional patents confirmed, priority chain from August 2025 through July 2026

Consecutive MAPK cancer pathway targets hit with a single molecular scaffold

HARMONY hasn't slowed down - it's compounded. New results, new patents, new targets.

Chase K. McMichael - Founder and CEO - July 2026

Investor Inquiries

Let's talk.

We respond to all serious inquiries within 48 hours. If you are a venture investor, family office, or strategic partner, fill out the form below.